Voltage-gated
sodium (Na
V
) channels are pore-forming
transmembrane proteins that play essential roles in excitable cells,
and they are key targets for antiepileptic, antiarrhythmic, and analgesic
drugs. We implemented a heterobivalent design strategy to modulate
the potency, selectivity, and binding kinetics of Na
V
channel
ligands. We conjugated μ-conotoxin KIIIA, which occludes the
pore of the Na
V
channels, to an analogue of huwentoxin-IV,
a spider-venom peptide that allosterically modulates channel gating.
Bioorthogonal hydrazide and copper-assisted azide–alkyne cycloaddition
conjugation chemistries were employed to generate heterobivalent ligands
using polyethylene glycol linkers spanning 40–120 Å. The
ligand with an 80 Å linker had the most pronounced bivalent effects,
with a significantly slower dissociation rate and 4–24-fold
higher potency compared to those of the monovalent peptides for the
human Na
V
1.4 channel. This study highlights the power of
heterobivalent ligand design and expands the repertoire of pharmacological
probes for exploring the function of Na
V
channels.